期刊
AMERICAN JOURNAL OF HEMATOLOGY
卷 97, 期 5, 页码 613-622出版社
WILEY
DOI: 10.1002/ajh.26510
关键词
-
类别
资金
- Bear Necessities Pediatric Cancer Foundation
- Children's Cancer Research Fund
- Higgins Charitable Foundation
- Midwest Athletes Against Childhood Cancer (MACC) Fund
- National Cancer Institute [P30CA014089]
- National Heart, Lung, and Blood Institute of the National Institutes of Health [T32HL007209]
- Medical College of Wisconsin Cancer Center Advancing Healthier Wisconsin Partnership Program
The combination of Decitabine and Vorinostat with FLAG showed promising efficacy in treating pediatric patients with R/R AML, especially those with epigenetic alterations. The therapy was well-tolerated and effective, with a significant proportion of patients achieving complete response and MRD negativity, leading to successful hematopoietic stem cell transplant. Correlative pharmacodynamics studies also revealed the biological activity of the drugs and identified specific gene enrichment signatures in nonresponding patients.
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. Epigenetic changes can result in gene expression alterations which are thought to contribute to both leukemogenesis and chemotherapy resistance. We report results from a phase I trial with a dose expansion cohort investigating decitabine and vorinostat in combination with fludarabine, cytarabine, and G-CSF (FLAG) in pediatric patients with R/R AML [NCT02412475]. Thirty-seven patients enrolled with a median age at enrollment of 8.4 (range, 1-20) years. There were no dose limiting toxicities among the enrolled patients, including two patients with Down syndrome. The recommended phase 2 dose of decitabine in combination with vorinostat and FLAG was 10 mg/m(2). The expanded cohort design allowed for an efficacy evaluation and the overall response rate among 35 evaluable patients was 54% (16 complete response (CR) and 3 complete response with incomplete hematologic recovery (CRi)). Ninety percent of responders achieved minimal residual disease (MRD) negativity (<0.1%) by centralized flow cytometry and 84% (n = 16) successfully proceeded to hematopoietic stem cell transplant. Two-year overall survival was 75.6% [95%CI: 47.3%, 90.1%] for MRD-negative patients vs. 17.9% [95%CI: 4.4%, 38.8%] for those with residual disease (p < .001). Twelve subjects (34%) had known epigenetic alterations with 8 (67%) achieving a CR, 7 (88%) of whom were MRD negative. Correlative pharmacodynamics demonstrated the biologic activity of decitabine and vorinostat and identified specific gene enrichment signatures in nonresponding patients. Overall, this therapy was well-tolerated, biologically active, and effective in pediatric patients with R/R AML, particularly those with epigenetic alterations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据